Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ftorafur

(tegafur)

Phase 3Small molecule

TThe First Affiliated Hospital with Nanjing Medical University

Tegafur is a chemotherapy drug used to treat certain types of cancer, including colorectal cancer and gastric cancer, by slowing or stopping the growth of cancer cells.[1] Ftorafur is currently being investigated across 10 indications[3], with its most advanced program in Phase 3.[1]

Ftorafur is one of 271 small molecule programs targeting Gastric Cancer. It is currently in Phase 3.

10

Indications

19

Total Trials

9

Active Trials

270

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric CancerNot yet recruiting

Pancreatic CancerUnknown status

Stomach NeoplasmUnknown

Head and Neck Malignant NeoplasiaUnknown

Non-Small Cell Lung CancerUnknown

Esophageal Squamous Cell CarcinomaRecruiting

Gastroesophageal Junction AdenocarcinomaRecruiting

AdenocarcinomaNot yet recruiting

RadiotherapyRecruiting

TislelizumabRecruiting

Gastric CancerPhase 3

Not yet recruiting

Pancreatic CancerPhase 3

Unknown status

Stomach NeoplasmPreclinical

Unknown

Head and Neck Malignant NeoplasiaPreclinical

Unknown

Non-Small Cell Lung CancerPreclinical

Unknown

Esophageal Squamous Cell CarcinomaPhase 3

Recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Recruiting

AdenocarcinomaPhase 2

Not yet recruiting

RadiotherapyPhase 2

Recruiting

TislelizumabPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Alecensa

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Firmonertinib

AAllist Pharmaceuticals, Inc.

JDQ443

ABP 234

Remeron

OOrganon and Co

Valemetostat Tosylate

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Efficacy and Safety

NCT06603974

Q2 2027

Phase 2Recruiting

Esophageal Squamous Cell Carcinoma

NCT06988956

Q4 2027

Phase 2Recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06461910

Phase 2Not yet recruiting

Pancreatic Cancer

NCT06383078

Q2 2028

Phase 2Recruiting

Tislelizumab

NCT06354140

Clinical

Trials by Indication[1]

Gastric Cancer3 trials

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Not yet recruiting·FFujian Medical University·Phase 3·NCT05914610·100 enrolled

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 3·NCT04135781·616 enrolled

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Completed·FFujian Cancer Hospital·Phase 2·NCT05223088·40 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06339619·32 enrolled

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06988956·95 enrolled

Advanced2 trials

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Completed·—·Phase 1·NCT03175679·10 enrolled

Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

Unknown status·—·Phase 1·NCT03175705·18 enrolled

Pancreatic Cancer2 trials

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06383078·120 enrolled

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT04216758·300 enrolled

Esophageal Cancer1 trial

Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

Unknown status·TTaizhou Hospital·Phase 2/3·NCT05817201·60 enrolled

9 more indications

Radiotherapy1 trial

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Recruiting·—·Phase 2·NCT07165847·40 enrolled

Biliary Tract Cancer1 trial

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

Completed·NNational Health Research Institutes, Taiwan·Phase 2·NCT03406299·92 enrolled

Gallbladder Carcinoma1 trial

Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma

Unknown status·—·Phase 2·NCT03702491·138 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting·ZZekuan Xu·Phase 2·NCT06461910·30 enrolled

Tislelizumab1 trial

PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

Recruiting·—·Phase 2·NCT06354140·45 enrolled

Chemotherapy1 trial

Combination Chemotherapy in Treating Patients With Resected Colon Cancer

Completed·NNSABP Foundation Inc·Phase 3·NCT00378716·1,608 enrolled

Efficacy and Safety1 trial

The Efficacy and Safety of Benmelstobart for GC/EGC

Not yet recruiting·XXijing Hospital·N/A·NCT06603974·48 enrolled

Pancreatic Neuroendocrine Tumor1 trial

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03204032·60 enrolled

Adenocarcinoma1 trial

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06396585·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for tegafur. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tegafur compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tegafur. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital with Nanjing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Thymidylate Synthase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe First Affiliated Hospital with Nanjing Medical University

Related News